Uy Ear has given his Buy rating due to a combination of factors that highlight Alkermes’ strong performance and future potential. The company’s third-quarter 2024 results were robust ...

The biopharma company's third-quarter report highlighted robust proprietary product performance, despite some weakness relating to its external revenue streams. Alkermes is a biopharmaceutical ...

Stifel Nicolaus upgraded shares of Alkermes (NASDAQ:ALKS – Free Report) from a hold rating to a buy rating in a research note released on Tuesday, Marketbeat Ratings reports. The firm currently has ...

Dublin, Ireland-based Alkermes plc was formed by the Sep 2011 merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies ... global biopharmaceutical company that utilizes proprietary ...

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs ...

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...

James Investment Research Inc. purchased a new stake in Alkermes ... Hedge funds and other institutional investors own 95.21% of the company’s stock. Alkermes plc, a biopharmaceutical company ...

The company's EPS beat by $0.02 in the last quarter, leading to a 5.77% increase in the share price on the following day. Shares of Alkermes were trading at $28.1 as of October 22. Over the last ...

DUBLIN (AP) — DUBLIN (AP) — Alkermes PLC (ALKS) on Thursday reported third-quarter profit of $92.4 million. On a per-share basis, the Dublin-based company said it had profit of 55 cents.

– 12 Poster Presentations Showcase Research in Schizophrenia, Bipolar I Disorder and Narcolepsy – – Results Presented From Real-World Retrospective Study of Healthcare Resource Utilization ...